Watch this on-demand webinar held on May , 2025, focusing on the use of a mAb platform from resin-based to membrane Protein A chromatography, evaluating productivity, material cost and plant occupancy at 50, 500 and 2000 L scales. Results indicate this technology’s potential benefits for clinical development and improved operational flexibility.
How Protein A membrane chromatography enhances monoclonal antibody (mAb) purification, offering higher throughput and reduced processing times
How this technology is implemented in a CRDMO setting for biologics development, particularly for FIH molecules
The key differences in productivity, cost efficiency and plant occupancy across different scales (50 L, 500 L, and 2000 L)
How this approach can optimize clinical development workflows and increase scalability for biologics manufacturing
Indraneel Sanyal
Senior Director, Process Development, Aragen Life Sciences
